Management of Patients with a Genetic Variant of Unknown Significance
Suzanne M MahonPublished in: Oncology nursing forum (2016)
Accurate risk assessment of developing cancer often includes genetic testing for germline mutations, which has clinical and treatment implications for the patient and his or her family members. When a mutation is detected, aggressive measures for cancer prevention and detection are often implemented. Depending on the gene or genes tested, a variable percentage of patients will receive a test report stating that a variant of unknown significance (VUS) has been detected. This means that a change in the genetic sequence has occurred, but whether the change is associated with an increased risk of cancer or another disease is unclear or unknown. The results are confusing and noninformative. Oncology nurses will undoubtedly encounter patients with a VUS; consequently, they need to understand the controversies and ambiguities that surround these test results. Resources that may be offered by healthcare providers and aid in patient understanding of VUS results are available (see Figure 1).
Keyphrases
- papillary thyroid
- healthcare
- genome wide
- risk assessment
- squamous cell
- end stage renal disease
- copy number
- case report
- chronic kidney disease
- mental health
- squamous cell carcinoma
- palliative care
- ejection fraction
- newly diagnosed
- high resolution
- peritoneal dialysis
- childhood cancer
- heavy metals
- gene expression
- lymph node metastasis
- young adults
- health information
- quantum dots
- label free
- health insurance
- loop mediated isothermal amplification